Bishop John E
Known title: See RemarksCIK: 0001308911
Associated companies
Transaction History
| ARDX | ▼ Sell | Open Market | 17,281 | $67K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,469 | $10K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,306 | $14K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,792 | $16K | 2/20/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 386 | $2K | 2/20/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 1 | $6 | 2/20/2026 | View on chart |
| ARDX | ▲ Buy | Grant | 124,330 | $0 | 1/23/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026
Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.